clinical trial · NCT07421232
A Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed Hyperlipidemia
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.·phase2·completed·n = 156
Hypercholesterolemia and Mixed HyperlipidemiaSYH2053/placebo injectionInclisiran (Leqvio®) 300mg
brief summary
The purpose of this study is to compare the effectiveness, safety of SYH2053 in Participants with primary hypercholesterolemia or mixed dyslipidemia. A total of 156 Participants were actually enrolled
started
Dec 3, 2024
primary completion
Aug 30, 2025
completion
Feb 12, 2026
last updated
Feb 19, 2026
official title
A Phase Ⅱ Randomized, Parallel-group, Placebo-controlled, Active-controlled Trial to Assess the Efficacy, Safety of the SYH2053 Subcutaneous Injection in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol